Published in Cancer Weekly, February 8th, 2005
Study 1: Protease inhibitor treatment increases the risk of chemotherapy-induced neutropenia in patients with AIDS-related non-Hodgkin lymphoma (ARL).
"Pharmacokinetic interactions between chemotherapy and highly active anti-retroviral therapy (HAART) are described, but there are few data on their clinical relevance," oncologists in England explained.
In a study conducted by M. Bower and coauthors at Chelsea and Westminster Hospital in London, patients with systemic ARL "were treated with concomitant HAART and infusional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-02-08)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.